Extended indication Influenza - treatment of hospitalised patients
Therapeutic value No judgement
Total cost 435,000.00
Registration phase Registration application pending

Product

Active substance Zanamivir
Domain Infectious diseases
Main indication Viral infections other
Extended indication Influenza - treatment of hospitalised patients
Proprietary name Relenza
Manufacturer GSK
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)
Additional remarks Betreft een nieuwe formulering als intraveneuze toediening. Neuraminidase inhibitor.

Registration

Registration route Centralised (EMA)
Particularity New medicine
Submission date January 2018
Expected Registration February 2019
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Current treatment options Oseltamivir
Therapeutic value No judgement
Duration of treatment Average 5 day / days
Frequency of administration 2 times a day
Dosage per administration 600 mg
References clinicaltrials.gov, NCT01527110

Expected patient volume per year

Patient volume

< 300

Market share is generally not included unless otherwise stated.

Additional remarks Inschatting werkgroep, maximaal 300 patiënten per jaar.

Expected cost per patient per year

Cost 1,400.00 - 1,500.00
References Medicijnkosten.nl
Additional remarks €4,85 voor een verpakking inhalers van 4 doses, 5 mg per dosis. Als het voor intraveneuze infusie een zelfde prijs zal worden komt dat neer op €1455 per patiënt per jaar.

Potential total cost per year

Total cost

435,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

References Mogelijke inzet bij preventie van infectie met influenza.

Indication extension

Indication extension No

Other information

There is currently no futher information available.